# Research Loop Progress

## Current Session: h49, h50, h51, h52, h53, h54 (2026-01-31)

### Session Summary

**Agent Role:** Research Executor
**Status:** Completed (6 hypotheses tested)
**Hypotheses Tested:**
- h49: Gene Expression → Drug Mapping Pipeline - **VALIDATED**
- h50: Rare Skin Disease Baseline Evaluation - **VALIDATED**
- h51: Gene Module Similarity for Disease Matching - **INVALIDATED**
- h52: Meta-Confidence Model for Prediction Reliability - **VALIDATED**
- h53: Skin Disease Name Mapping Expansion - **VALIDATED**
- h54: Production Meta-Confidence Pipeline - **VALIDATED**

### Results Summary

| Hypothesis | Status | Key Finding |
|---|---|---|
| h49 | **VALIDATED** | Gene→Drug pipeline: known drugs rank 88.1 percentile |
| h50 | **VALIDATED** | Skin diseases: 54.87% R@30 (+22 pp vs baseline) |
| h51 | **INVALIDATED** | Gene Jaccard -14.71 pp vs Node2Vec |
| h52 | **VALIDATED** | Meta-confidence AUC 0.733, HIGH tier 89.7% hit rate |
| h53 | **VALIDATED** | +17.9% skin disease coverage (39 → 46 diseases) |
| h54 | **VALIDATED** | Production model: HIGH tier 100%, LOW tier 7.5% |

### Key Deliverables Created

1. **Gene Expression → Drug Mapping Pipeline**
   - Script: `scripts/gene_expression_drug_mapping.py`
   - Data: `data/reference/drug_to_genes_drkg.json`, `gene_to_drugs_drkg.json`
   - 19,089 drugs, 19,565 genes, 155,765 edges

2. **Meta-Confidence Pipeline**
   - Model: `models/meta_confidence_model.pkl`
   - Helper: `models/meta_confidence_helper.py`
   - HIGH tier: 100% hit rate, LOW tier: 7.5%

3. **Expanded Skin Disease Mappings**
   - 26 manual MESH mappings added
   - Coverage: 39 → 46 skin diseases (+17.9%)

### Current Metrics

| Model | R@30 | Notes |
|-------|------|-------|
| kNN Collaborative Filtering k=20 | 37.04% ± 5.81% | Best overall |
| kNN on Skin Diseases | 54.05% ± 9.40% | +22 pp vs baseline |
| kNN on Rare Skin Diseases | 62.18% ± 37.70% | High variance |

### Remaining Pending Hypotheses

1. h55: GEO Gene Expression Data Integration (Priority 3, high effort)
2. h56: Cancer Category Analysis Deep Dive (Priority 4, low effort)
3. h16: Clinical Trial Phase Features (Priority 20, low impact)

### Recommended Next Steps

1. **h56: Cancer Category Analysis** - Low effort, explains meta-confidence finding
2. **Deploy Meta-Confidence Tiering** - HIGH tier predictions ready for production
3. **Expand Ground Truth for Skin Diseases** - Query additional sources
4. **h55: GEO Integration** - High effort but could bypass DRKG limitations
